» Articles » PMID: 34054556

Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

Overview
Journal Front Pharmacol
Date 2021 May 31
PMID 34054556
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging evidence indicates that early-life exposure to environmental factors may increase the risk for schizophrenia via inflammatory mechanisms. Inflammation can alter the metabolism of tryptophan through the oxidative kynurenine pathway to compounds with neurotoxic and neuroprotective activity and compromise serotonin (5-HT) synthesis. Here we investigate the role of serotonergic and kynurenine pathways in the maternal immune activation (MIA) animal model of schizophrenia. The potential reversion exerted by long-term antipsychotic treatment was also evaluated. MIA was induced by prenatal administration of polyinosinic:polycytidylic acid (poly (I:C)) in mice. Expression of different proteins and the content of different metabolites involved in the function of serotonergic and kynurenine pathways was assessed by RT-PCR, immunoblot and ELISA analyses in frontal cortex of the offspring after puberty. MIA decreased tissue 5-HT content and promoted changes in the expression of serotonin transporter, 5-HT and 5-HT receptors. Expression of indoleamine 2,3-dioxygenase 2 (IDO2) and kynurenine 3-monooxygenase (KMO) was increased by poly (I:C) whereas kynurenine aminotransferase II and its metabolite kynurenic acid were not altered. Long-term paliperidone was able to counteract MIA-induced changes in 5-HT and KMO, and to increase tryptophan availability and tryptophan hydroxylase-2 expression in poly (I:C) mice but not in controls. MIA-induced increase of the cytotoxic risk ratio of kynurenine metabolites (quinolinic/kynurenic acid) was also reversed by paliperidone. MIA induces specific long-term brain effects on serotonergic activity. Such effects seem to be related with alternative activation of the kynurenine metabolic pathway towards a cytotoxic status. Atypical antipsychotic paliperodine partially remediates abnormalities observed after MIA.

Citing Articles

Perinatal Hypoxia and Immune System Activation in Schizophrenia Pathogenesis: Critical Considerations During COVID-19 Pandemic.

Kawikova I, Hakenova K, Lebedeva M, Kleteckova L, Jakob L, Spicka V Physiol Res. 2024; 73(S2):S615-S639.

PMID: 39589306 PMC: 11627263.


Does the kynurenine pathway play a pathogenic role in autism spectrum disorder?.

Santana-Coelho D Brain Behav Immun Health. 2024; 40:100839.

PMID: 39263315 PMC: 11387593. DOI: 10.1016/j.bbih.2024.100839.


Maternal Immune Activation Induces Cortical Catecholaminergic Hypofunction and Cognitive Impairments in Offspring.

Perez-Palomar B, Erdozain A, Erkizia-Santamaria I, Ortega J, Meana J J Neuroimmune Pharmacol. 2023; 18(3):348-365.

PMID: 37208550 PMC: 10577104. DOI: 10.1007/s11481-023-10070-1.


Maternal Inflammation with Elevated Kynurenine Metabolites Is Related to the Risk of Abnormal Brain Development and Behavioral Changes in Autism Spectrum Disorder.

Murakami Y, Imamura Y, Kasahara Y, Yoshida C, Momono Y, Fang K Cells. 2023; 12(7).

PMID: 37048160 PMC: 10093447. DOI: 10.3390/cells12071087.


Examining the immune signatures of SARS-CoV-2 infection in pregnancy and the impact on neurodevelopment: Protocol of the longitudinal study.

Garrido-Torres N, Cerrillos L, Garcia Cerro S, Perez Gomez A, Canal-Rivero M, De Felipe B Front Pediatr. 2023; 10:899445.

PMID: 36619503 PMC: 9811261. DOI: 10.3389/fped.2022.899445.


References
1.
Crow T, Baker H, Cross A, Joseph M, Lofthouse R, Longden A . Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br J Psychiatry. 1979; 134:249-56. DOI: 10.1192/bjp.134.3.249. View

2.
Meyer U, Knuesel I, Nyffeler M, Feldon J . Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology (Berl). 2009; 208(4):531-43. DOI: 10.1007/s00213-009-1754-6. View

3.
LOVETT DOUST J, Huszka L, Lovett Doust J . Psychotropic drugs and gender as modifiers of the role of plasma tryptophan and serotonin in schizophrenia. Compr Psychiatry. 1975; 16(4):349-55. DOI: 10.1016/s0010-440x(75)80005-8. View

4.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M . Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005; 38(6):301-11. DOI: 10.1055/s-2005-916185. View

5.
Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee B, Feldon J . Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology. 2007; 33(2):441-56. DOI: 10.1038/sj.npp.1301413. View